At the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO) held from May 29 to June 2, 2026, Simcere Zaiming will present nine clinical studies featuring its self-developed innovative ADC drug SIM0505 and five marketed innovative therapies, covering multiple solid tumor areas including advanced colorectal cancer, gastric cancer, biliary tract malignancies, and osteosarcoma.
SIM0505（CDH6 ADC）
Poster：Phase I, multicenter, first-in-human (FIH) global study of SIM0505, an anti-CDH6 (CDH6) antibody-drug conjugate (ADC) in patients with advanced solid tumors.
Presenter：
Presenter: Xiaohua Wu
Date: Jun 1, 2026
Abstract: 5580
SIM0505 is a globally first-in-class CDH6-targeted ADC candidate independently developed by Simcere Zaiming. The drug is currently being evaluated in parallel global multicenter Phase I clinical trials in both China and the United States. The poster presented at this year’s ASCO meeting provides preliminary evidence of the therapeutic potential of SIM0505 in patients with advanced solid tumors.
Enweida(Envafolimab)
Poster: Envafolimab (KN035) plus gemcitabine and oxaliplatin (GEMOX) compared with GEMOX as first-line treatment for Chinese patients with advanced biliary tract cancer: A randomized, open-label, multi-center, phase III pivotal trial.
Presenter: Shukui Qin, MD
Date: May 30, 2026
Abstract: 4118
The world’s first global Phase III clinical study to evaluate immunotherapy combined with chemotherapy for advanced biliary tract cancer, led by Chinese investigators, demonstrated that the subcutaneous PD-L1 inhibitor Envafolimab in combination with gemcitabine and oxaliplatin (GEMOX) has the potential to become a new standard treatment regimen for advanced biliary tract cancer.
Posters：Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A multicenter, single-arm, open-label, phase ll study (ENLIGHTEN study).
Presenter: Lixia Xu, PhD
Date: May 30, 2026
Abstract: 4152
E-abstract：Short-course radiotherapy and chemotherapy with or without PD-L1 blockade (envafolimab) for MSS locally advanced rectal cancer: Interim analysis of the randomized phase Ⅲ PRECAM-R trial.
Presenter: Yiming Lv, MD
Abstract: e15636
E-abstract：A prospective, single-arm, single-center observational clinical study on envafolimab (PD-L1 inhibitor) in combination with XELOX for neoadjuvant treatment of locally advanced colon cancer.
Presenter: Hui Li
Abstract: e15654
Enlituo(cetuximab β)
Posters：CONCEPT (combination of cetuximab plus fruquintinib treatment + immunotherapy): A multicenter randomized, open-label phase ll trial in first-line pMMR RAS/BRAF wild-type unresectable metastatic colorectal cancer.
Presenter: Yue Liu, MD
Date: May 30, 2026
Abstract: TPS3680
Endostar (Recombinant human endostatin)
Posters：Efficacy and safety of continuous intra-arterial cisplatin and recombinant human endostatin combined with systemic chemotherapy in osteosarcoma: A phase ll study.
Presenter: Hongtao Li, MD
Date: Jun 2, 2026
Abstract: 11523
Enzeshu（Suvemcitug）
Posters：A phase lb/Ⅲ randomized double-blinded placebo-controlled study of suvemcitug combined with trifluridine/tipiracil for refractory metastatic colorectal cancer.
Presenter: Ying Yuan, MD, PhD
Date: May 30, 2026
Abstract: TPS3674
Cosela(Trilaciclib）
E-abstract：Trilaciclib for myelo-protection in adjuvant and first-line chemotherapy for advanced gastric/gastroesophageal junction adenocarcinoma: A multicohort study.
Presenter: Wenhui Yang
Date: May 31, 2026
Abstract: 12152